Short time administration of antirheumatic drugs - Methotrexate as a strong inhibitor of osteoblast's proliferation in vitro
Open Access
- 29 September 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Head & Face Medicine
- Vol. 8 (1), 26
- https://doi.org/10.1186/1746-160x-8-26
Abstract
Introduction: Due to increasing use of disease modifying antirheumatic drugs (DMARDs) as first line therapy in rheumatic diseases, dental and maxillofacial practitioner should be aware of drug related adverse events. Especially effects on bone-metabolism and its cells are discussed controversially. Therefore we investigate the in vitro effect of short time administration of low dose methotrexate (MTX) on osteoblasts as essential part of bone remodelling cells. Methods: Primary bovine osteoblasts (OBs) were incubated with various concentrations of MTX, related to tissue concentrations, over a period of fourteen days by using a previously established standard protocol. The effect on cell proliferation as well as mitochondrial activity was assessed by using 3-(4, 5-dimethylthiazol-2-yl) 2, 5-diphenyltetrazolium bromide (MTT) assay, imaging and counting of living cells. Additionally, immunostaining of extracellular matrix proteins was used to survey osteogenic differentiation. Results: All methods indicate a strong inhibition of osteoblast`s proliferation by short time administration of low ose MTX within therapeutically relevant concentrations of 1 to 1000nM, without affecting cell differentiation of middle-stage differentiated OBs in general. More over a significant decrease of cell numbers and mitochondrial activity was found at these MTX concentrations. The most sensitive method seems to be the MTT-assay. MTX-concentration of 0,01nM and concentrations below had no inhibitory effects anymore. Conclusion: Even low dose methotrexate acts as a potent inhibitor of osteoblast’s proliferation and mitochondrial metabolism in vitro, without affecting main differentiation of pre-differentiated osteoblasts. These results suggest possible negative effects of DMARDs concerning bone healing and for example osseointegration of dental implants. Especially the specifics of the jaw bone with its high vascularisation and physiological high tissue metabolism, suggests possible negative effects of DMARD therapy concerning oral and cranio-maxillofacial bone surgery as could be seen in a similar way in bisphosphonate related osteonecrosis of the jawKeywords
This publication has 24 references indexed in Scilit:
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care & Research, 2012
- The Pathogenesis of Rheumatoid ArthritisThe New England Journal of Medicine, 2011
- Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2010
- An update on methotrexateCurrent Opinion in Rheumatology, 2009
- Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature researchAnnals Of The Rheumatic Diseases, 2008
- The pharmacogenetics of methotrexateRheumatology, 2007
- Epidemiology of adult rheumatoid arthritisAutoimmunity Reviews, 2005
- Effects of methotrexate on human osteoblasts in vitro: Modulation by 1,25-dihydroxyvitamin D3Journal of Bone and Mineral Research, 1995
- Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patientsArthritis & Rheumatism, 1994
- Biochemical signal transduction of mechanical strain in osteoblast-like cellsBiomaterials, 1991